Monte Nido logo
Treatment
What we treat
What we treatAnorexia NervosaAtypical AnorexiaBulimia NervosaBinge Eating
See all
Who we serve
Who we serveAdolescentsAll gendersFamilies and loved onesAthletes
See more
Programs
Our programsVirtual treatmentDay treatmentResidential treatmentInpatient treatment
Admissions
AdmissionsInsurance CheckerFinancial considerationsFAQ
APPROACH
Our approachTherapeutic philosophyNutrition

Do I have an eating disorder?

This 2-minute quiz can help you see if you or your loved one might have an eating disorder.

Take the screening assessment
Locations
ArizonaArizona
CaliforniaCalifornia
ColoradoColorado
ConnecticutConnecticut
FloridaFlorida
GeorgiaGeorgia
IdahoIdaho
IllinoisIllinois
MaineMaine
MarylandMaryland
MassachusettsMassachusetts
MissouriMissouri
MontanaMontana
NevadaNevada
New HampshireNew Hampshire
New JerseyNew Jersey
New YorkNew York
North CarolinaNorth Carolina
OhioOhio
OregonOregon
PennsylvaniaPennsylvania
Rhode IslandRhode Island
South CarolinaSouth Carolina
TennesseeTennessee
TexasTexas
UtahUtah
VermontVermont
VirginiaVirginia
WashingtonWashington
VirtualVirtual
a map of the united states of the united states

Discover the Nearest Location

Get matched with our nearest location by sharing a bit about yourself.

Find a locationSeek virtual care
For You
For loved ones
Arrow Right
For clients & alumni
Arrow Right
Caring for loved onesVirtual support groupsResources for loved ones
For alumni
Post-treatment supportVirtual support groups for alumniResources
Documents
Request a medical record

Latest content for loved ones

See all
May 15, 2025
Causes of Body Image Issues in Adolescence
May 12, 2025
6 Facts About Binge Eating Disorder You Might Not Have Known
May 9, 2025
What to Do If You Think Your Child Has Bulimia Nervosa

Latest content for you

See all
May 19, 2025
Eating Disorders and Co-Occurring Mental Health Conditions
May 12, 2025
6 Facts About Binge Eating Disorder You Might Not Have Known
March 17, 2025
How a Dietitian Can Help with Eating Disorders
Placeholder
For Providers
Referrals 101
Outpatient ProvidersFacilities & Hospitals
Continuing educationMeet our Outreach Team
Refer now: Outpatient Providers
Refer now: Facilities & Hospitals

Latest content for providers

See all
May 14, 2025
Unpacking Asian American Eating Disorders and Cultural Influences
April 9, 2025
What is ARFID? Understanding Diagnosis and Treatment
March 12, 2025
Attention Needed: Navigating ADHD and Eating Disorders
About Us
About us
What Monte Nido isOur latest outcomes reportTrusted outcomesLeadershipAdvocacy
Reference
TestimonialsOur work in the newsBlog
Admissions
AdmissionsInsurance CheckerFinancial considerationsFAQ
Join
Careers
Reach out to us
888-228-1253
Reach out to us
Home
Blog
GLP-1A Culture and its Impact on Eating Disorder Treatment
Home
Blog
GLP-1A Culture and its Impact on Eating Disorder Treatment
For you
For loved ones
For providers

GLP-1A Culture and its Impact on Eating Disorder Treatment

February 3, 2025

4 min read

Monte Nido

The rise of GLP-1A culture

As the use and availability of GLP-1 receptor agonists (GLP-1RAs) continue to rise, the eating disorder community must start having conversations about how to approach this shift. While medications like Ozempic and Wegovy are approved for treating conditions like diabetes, they are increasingly being used for weight loss. With over 120 similar drugs currently in development, it's crucial to better understand how GLP-1RAs—whether prescribed for diabetes or weight management—affect eating disorder treatment, especially for binge eating disorder. As the debate over weight loss intensifies, the growing focus on weight stigma can contribute to feelings of hopelessness and lowered self-confidence in individuals in larger bodies. This desire for an “easy fix” to weight concerns is also leading to medication shortages, which impacts people who are prescribed GLP-1RAs for other medical conditions. There needs to be greater concern in the medical field about the potential effects of these medications on individuals struggling with eating disorders.

{{blog-button="/cta-buttons"}}

What are GLP-1As?

GLP-1RAs are approved for diabetes management in the U.S., Canada, and other countries, and are available as both pills and injections. These medications regulate blood glucose by stimulating insulin release and suppressing glucagon production.1 They also slow stomach emptying and affect brain pathways that control appetite, which can increase feelings of fullness and reduce food intake.

While GLP-1RAs are effective, they come with side effects. These can include nausea, vomiting, abdominal pain, diarrhea, and constipation, while rarer but more serious issues can also occur. There is limited research on their long-term effects.2

GLP-1RAs are celebrated for weight loss in adults, though this loss plateaus over time and the weight can be substantially regained after stopping the medication.3, 4, 5, 6  Currently, GLP-1RAs are not approved for eating disorder treatment.

In terms of short-term weight loss, GLP-1RAs show effectiveness. For example, the STEP 2 study on semaglutide with lifestyle changes showed an average weight loss of 33.7 lbs over 68 weeks, compared to just 5.7 lbs without the medication.4, 6 However, weight loss typically slows after this period, and some participants even gained weight, diminishing the overall effect.  

Effectiveness of binge eating disorder treatment and GLP-1As

Caloric restriction can directly conflict with the goals of eating disorder treatment, and the current studies on GLP-1RAs are insufficient to draw meaningful conclusions. More targeted research is needed, specifically examining how GLP1-RAs affect eating disorder behaviors. This includes differentiating between pathological and non-pathological restriction, tracking client outcomes over extended periods, exploring the misuse of these medications in eating disorder populations, and understanding how binge eating would likely rebound significantly once the medication’s appetite-suppressing effects wear off.4

As the use of GLP-1RAs increases, it's crucial for eating disorder treatment programs to prepare for a growing number of clients who are already using these medications.

Approaching this issue with empathy is essential. Understanding why a client is taking GLP-1As, particularly if it's for weight loss, helps inform the risk assessment. The potential risks need to be weighed carefully to determine if they outweigh the benefits for the client’s treatment.

Evidence-based treatments for binge eating, such as therapy and non-weight-loss prescription medications, are already available and proven as effective treatment.

In a treatment setting that emphasizes regular meals and mindful eating, medications that reduce appetite can create significant challenges. Side effects may disrupt the ability to follow a structured meal plan, leading to discomfort and potential setbacks in treatment.

Moreover, GLP-1RAs can be misused as a way to manage negative body image related to weight and weight gain. This unhealthy usage can prevent clients from reconnecting with their natural hunger and fullness cues and hinder their ability to process emotions about body size and shape.  

Navigating the intersection of eating disorder treatment and weight loss medications

When navigating the use of GLP-1As in eating disorder treatment, it’s essential to recognize that if a client meets the criteria for this medication, the decision to continue or discontinue it during treatment ultimately is theirs. However, clinicians should ensure that clients are fully informed about the potential risks and benefits of using these medications in the context of their treatment. The provider then needs to assess the overall impact on eating disorder treatment and whether or not it is feasible or too risky to do.

For clients taking GLP-1RAs in relation to binge eating disorder, it’s crucial to explain that binge eating is often a physiological response to restriction. GLP-1As, which suppress appetite, can exacerbate restriction and ultimately contribute to cycles of binge eating.4 Since GLP-1RAs are not approved for binge eating and there is limited research on their efficacy for this condition, it’s important to highlight other evidence-based treatments which may be more appropriate. Be transparent that if the client discontinues the medication, they may experience an increase in binge episodes.  They need to know that weight loss in itself can negatively impact their relationship with food and ultimately their success in eating disorder treatment.

Even if a client is prescribed GLP-1RAs, they may remain eligible for binge eating disorder treatment. However, clinicians should be aware that these medications may interfere with the client’s ability to adhere to a structured eating plan, which is a key component in eating disorder recovery.

The conversation about GLP-1RAs should begin with respect for the client’s autonomy in making medical decisions. It’s important to understand why the client is taking the medication and whether it’s serving the intended purpose such as diabetes treatment. If the client is using GLP-1As for weight loss, acknowledge the broader societal context of weight stigma and the pervasive influence of diet culture, which may lead them to seek weight loss solutions. Validating their feelings and offering empathy can help create a productive dialogue.  

Although the conversation surrounding GLP-1RAs in the eating disorder field can be contentious, it’s important to lead with empathy and recognize all that goes into making the decision to take weight loss medications.  

Sources:

  1. Food and Drug Administration (FDA). (2022) Ozempic (semaglutide) injection precribing information, revised. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637Orig1s009lbl.pdf
  1. Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024). Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. International Journal of Eating Disorders, 57(2), 286–293. https://doi.org/10.1002/eat.24109
  1. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., STEP 4 Investiga- tors, Friberg, M., Sjödin, A., Dicker, D., Segal, G., ... STEP 4 Investiga- tors. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obe- sity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
  1. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O'Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., Garvey, W. T., & STEP 3 Investigators. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 325(14), 1403– 1413. https://doi.org/10.1001/jama.2021.1831
  1. Wilding, J. P., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after with- drawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
  1. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... Lingvay, I. (2021). Semaglutide 2 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A ran- domised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

 

Most recent articles

illustration of people profiles
For you
May 19, 2025
7 min read

Eating Disorders and Co-Occurring Mental Health Conditions

Read more
Young girl with headphones looking mirror taking a selfie
For loved ones
May 15, 2025
8 min read

Causes of Body Image Issues in Adolescence

Read more
For providers
May 14, 2025
10 min read

Unpacking Asian American Eating Disorders and Cultural Influences

Read more
Monte Nido
Text Link
For you
For loved ones
For providers

Everybody deserves a full life

Recovery is possible for everyone. We’re here to help you get started.
  • - -
  • Level of care client is interested in

  • By submitting this form, I agree to Monte Nido's Privacy Policy & Terms of Use

  • Should be Empty:
or call
888-228-1253
to speak confidentially with one of our eating disorders specialists to start the road to recovery.
Treatment
  • What we treat
  • Who we serve
  • Our programs
  • Admissions
  • Financial considerations
  • FAQ
  • Our approach
  • Eating disorder quiz
Locations
  • All locations
  • Arizona
  • California
  • Colorado
  • Connecticut
  • Florida
  • Georgia
  • Idaho
  • Illinois
  • Maine
  • Maryland
  • Massachusetts
  • Missouri
  • Montana
  • Nevada
  • New Hampshire
  • New Jersey
  • New York
  • North Carolina
  • Ohio
  • Oregon
  • Pennsylvania
  • Rhode Island
  • South Carolina
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • Virtual
For You
For loved ones
  • Caring for loved ones
  • Virtual support groups
  • Resources for loved ones
For clients & alumni
  • Post-treatment support
  • Virtual support groups for alumni
  • Request a medical record
  • Resources
for providers
  • Referrals 101
  • Continuing education
  • Meet our Outreach Team
About Us
  • What Monte Nido is
  • Trusted outcomes
  • Leadership
  • Advocacy
  • Testimonials
  • Our work in the news
  • Blog
  • Glossary
  • Careers
Contact Us
  • Reach out to us
  • Request a medical record
Monte Nido logo
Monte Nido Walden LogoMonte Nido Clementine LogoMonte Nido Rosewood Logo
Accredited by Joint Commission, and proud members of the Residential Eating Disorder Consortium and Eating Disorders Coalition
REDC, EDC, APA logos
888-228-1253
© 2024 Monte Nido. All rights reserved.
Accessibility Policy
Data Notification
Privacy Policy
Privacy Practices
Terms and Conditions